Targovax ASA [TRVX.OTC] today announced that executives from the company will present at three investor conferences in the months of November and December 2015:
- CEO Gunnar Gårdemyr will be speaking to investors at a RedEye forum on immune-oncology in Stockholm on Tuesday 10 November
- CFO Oystein Soug will hold a presentation at Arctic Securities’ Biotech Seminar in Oslo on Monday 30 November, and
- CEO Gunnar Gårdemyr and CMO Magnus Jaderberg will be speaking at DNB Markets’ Healthcare Conference in Oslo on Tuesday 15 December. CFO Oystein Soug will also be present at the conference
The presentations will be accessible through the Investor Relations portion of the Targovax website Visit http://www.targovax.com/investor-relations.
For more information, please contact:
Chief Financial Officer
+47 90 65 65 25
Targovax is a clinical stage immuno-oncology company dedicated to the development of highly targeted immunotherapies for cancer patients. The company is developing two complementary and highly targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. Both treatment approaches harness the patient’s own immune system to fight cancer. Targovax is headquartered in Oslo with an office in Helsinki.